**Company Profile**

**Industry Sector:** Development of Brain Neuroprotective Drugs  
Diagnostic Biomarkers for Brain Inflammation

**Company Overview:** The team at InFlame™Therapeutics has discovered cellular and biochemical pathways that account for memory loss and dementia caused by brain inflammation. Such inflammation, involving cells called microglia, occurs in both Alzheimer’s disease and HIV brain infection, affecting more than 4.5 million patients in the US alone. Currently, there are no effective disease-modifying drugs to treat these brain disorders. Through the use of unique microglia-based assays and animal models, we screen for brain protective drugs; by monitoring a disease biomarker, we accelerate the pace of clinical testing.


---

**Management and Structure**

Laura A. Jacobus, CEO, *InFlame™ Therapeutics*

Dana Giulian, M.D., Ph.D., CSO, *InFlame™ Therapeutics*

**Funding:**  
STTR awards (R42NS046997, R42AG022805)  
SBIR Awards (R43NS051120, R43NS052068, R44NS52068)

**Collaboration:**  
Guy Schiehser, Ph.D., Director of Chemistry at JPC  
Former Director of Medicinal Chemistry at Wyeth-Ayerst Research

---

**Pipeline and Product Development**

**Cell-Based Screening Assays:** tools to identify drug leads for neuroprotection; US Patents 6,071,493; 6,475,742; and 6,475,745.

**ENCEPHALOTOXIN™:** biomarker of brain inflammation; US Patent 7,344,852 for composition and use; Phase 2 clinical trial initiated.

**Novel Animal Models:** for preclinical testing of Alzheimer’s disease therapeutics; program has successfully identified 3 novel treatment regimens.

**Sustained-Release Drug Formulation:** drug combination for treatment of brain inflammation occurring in HIV cognitive disorders; Phase 1 clinical trial completed; Phase 2 study to begin. US patent filed.

**Novel Drugs for Brain Protection:** novel agents that prevent brain injury in Alzheimer’s disease. Pre-clinical testing phase to be completed by end of year.